Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-ARM trial of radiotherapy added to atezolizumab in advanced urothelial cancer
ISRCTN12606219Phase 2Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and avelumab in transitional cell carcinoma (TCC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Objective response rate by RECIST v1.1 at 9 weeks. Started Jul 2021; status: completed.
02
Drugs
atezolizumabavelumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ISRCTN12606219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12606219.